Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
Conclusions:
Degarelix monotherapy produced a more favorable effect on PSA PFS outcomes than a LHRH agonist + AA flare protection therapy in patients with prostate cancer when a case-control analysis was used to compensate for differences between treatment groups.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Authors: Iversen, P., Damber, J.-E., Malmberg, A., Persson, B.-E., Klotz, L. Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Hormones | Prostate Cancer | Study | Urology & Nephrology